Contact us on +44 (0)1270 270010 |


Brexit – medicines regulation outside the EU

As the Brexit transition period has now ended, the team at Boyds is continuing to support clients with the new guidance and regulations.

Furthermore, our Dublin office provides the foothold in Europe to ensure our clients can continue to benefit from access to the European Medicines Agency.

As the picture continues to evolve, we will bring you the latest updates from the regulatory authorities and post updates on this page. We also produce a monthly Regulatory Intelligence Digest (latest copies can be found below) and you can follow us on twitter @boydconsultants to keep up to date with the latest guidance and advice.

Get in touch to speak to the member of the team.

Latest Updates

Sign up here for the monthly Regulatory Affairs Digest.

* indicates required

Regulatory Affairs Digest

The regulatory team at Boyds regularly reviews all the latest developments from the regulatory authorities during the Brexit transition. Below are links to recent issues of our digest. To sign up and receive these direct to your inbox, complete the sign-up form on this page.

Regulatory Intelligence Digest – February 2021

Regulatory Intelligence Digest – January 2021

Regulatory Intelligence Digest – December 2020

Regulatory Intelligence Digest – November 2020

Regulatory Intelligence Digest – October 2020

Regulatory Intelligence Digest – September 2020